Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

Histologically proven NSCLC diagnosis
Life expectancy over four weeks
absolute neutrophil count ≥ 2.0X109/L, Pt ≥ 100X109/L, hemoglobin ≥ 90g/l
With normal hepatic function(AST, ALT \< 2.5 x upper limit of normal , and Total bilirubin ≤ upper limit of normal)
Suitable for EGFR-TKIs treatment and expectant duration over four weeks
No specific therapies received within 4 weeks prior to enrollment which may induce similar skin reaction,such as Cetuximab, Sorafenib, Avastin.
With a pre-existing peripheral neuropathy (National Cancer Institute Common Toxicity Criteria for Adverse Events \[NCI-CTC\] grade ≥ 3)
No other concomitant therapy referred to the face skin during the study
Signed and dated informed consent

Performance status ≥ 3(ECOG)
Pregnant or breast-feeding patients
The lesion counts can't be evaluated due to concomitant diseases or other conditions
Not suitable for EGFR-TKIs treatment

Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC